Papers/PMID:36307427
Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.
Scientific reports2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
magnesium(2+) — increases HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Those who received magnesium supplementation had significantly higher levels of HDL-cholesterol compared to the placebo group at the end of the study (49.7 ± 10.9 vs 43.6 ± 7.2 mg/dL, P = 0.003; estimated statistical power 0.90).”
Quoted verbatim from Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 250 mg magnesium as magnesium oxide tablet once daily
- Population
- People with prediabetes aged 18 to 65 in Isfahan, Iran, 12-week double-blind placebo-controlled trial; 71 completers (34 magnesium, 37 placebo)
Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.2022PMID:36307427Permalink